Striatal pre- and postsynaptic profile of adenosine a2a receptor antagonists

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Orru, Marco ^a   Bakešová, Jana ^b   Brugarolas, Marc ^b   Quiroz, César ^a   Beaumont, Vahri ^c   Goldberg, Steven R ^a   Lluís, Carme ^b   Cortés, Antoni ^b   Franco, Rafael ^b   Casadó, Vicent ^b   Canela, Enric I ^b   Ferré, Sergi ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FURANYL) 7 [3 (4 METHOXYPHENYL)PROPYL] 7H PYRAZOLO[4,3 C][1,2,4]TRIAZOLO[1,5 C]PYRIMIDIN 5 AMINE; 3 (3 HYDROXYPROPYL) 8 [2 (3 METHOXYPHENYL)VINYL] 7 METHYL 1 PROP 2 YNYL 3,7 DIHYDROPURINE 2,6 DIONE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; ISTRADEFYLLINE; MSX 2; MSX 3; PHOSPHORIC ACID MONO [3 [8 [2 (3 METHOXYPHENYL)VINYL] 7 METHYL 2,6 DIOXO 1 PROP 2 YNYL 1,2,6,7 TETRAHYDROPURIN 3 YL]PROPYL]ESTER; PRELADENANT; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; PRESYNAPTIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; RAT; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; DYSKINESIA; EFFERENT NERVE; NERVE CELL; PARKINSON DISEASE; POSTSYNAPTIC DENSITY; PROTEIN MULTIMERIZATION; SPRAGUE DAWLEY RAT; SYNAPSE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CORPUS STRIATUM; DYSKINESIAS; EFFERENT PATHWAYS; MALE; NEURONS; PARKINSON DISEASE; POST-SYNAPTIC DENSITY; PROTEIN MULTIMERIZATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PRESYNAPTIC; SYNAPSES;

EID: 79251549825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016088     Document Type: Article

References (31)

1. Gerfen CR (2004) Basal Ganglia. In: Paxinos G, ed. The Rat Nervous System. Amsterdam: Elsevier Academic Press. pp 445-508.
2. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Arbizu J, Giménez-Amaya JM (2002) The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol Sci 17: 51-55.
3. DeLong MR, Wichmann T (2007) Circuits and circuit disorders of the basal ganglia. Arch Neurol 64: 20-24.
4. Ferre S, Quiroz C, Woods AS, Cunha R, Popoli P, et al. (2008) An update on adenosine A2A-dopamine D2 receptor interactions: Implications for the function of G protein-coupled receptors. Curr Pharm Des 14: 1468-1474.
5. Quiroz C, Lujan R, Uchigashima M, Simoes AP, Lerner TN, et al. (2009) Key Modulatory Role of Presynaptic Adenosine A2A Receptors in Cortical Neurotransmission to the Striatal Direct Pathway. TheScientific World Journal 9: 1321-1344.
6. Azdad K, Gall D, Woods AS, Ledent C, Ferré S, et al. (2009) Dopamine D2 and adenosine A2A receptors regulate NMDA-excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 34: 972-986.
7. Higley MJ, Sabatini BL (2010) Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 13: 958-966.
8. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, et al. (2000) Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 97: 1856-1860.
9. Hakansson K, Galdi S, Hendrick J, Snyder G, Greengard P, et al. (2006) Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem 96: 482-488.
10. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, et al. (2001) The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A 98: 1970-1975.
11. Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueno J, et al. (2006) Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26: 2080-2087.
12. Quiroz C, Pearson V, Gulyani S, Allen R, Earley C, et al. (2010) Up-regulation of striatal A2A receptors with iron deficiency in rats. Effects on locomotion and cortico-striatal neurotransmission. Exp Neurol 224: 292-298.
13. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, et al. (2009) Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5: 131-134.
14. Ferré S, Ciruela F, Woods AS, Lluis C, Franco R (2007) Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci 30: 440-446.
15. Quarta D, Ferré S, Solinas M, You Z-B, Hockemeyer J, et al. (2004) Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and NMDA receptor stimulation. J Neurochem 91: 873-880.
16. Navarro G, Aymerich MS, Marcellino D, Cortés A, Casadó V, et al. (2009) Interactions between calmodulin, adenosine A2A and dopamine D2 receptors. J Biol Chem 284: 28058-28068.
17. Sarrió S, Casadó V, Escriche M, Ciruela F, Mallol J, et al. (2000) The heat shock cognate protein hsc73 assembles with A1 adenosine receptors to form functional modules in the cell membrane. Mol Cell Biol 20: 5164-5174.
18. Franco R, Casadó V, Mallol J, Ferré S, Fuxe K, et al. (2005) Dimer-based model for heptaspanning membrana receptors. Trends Biochem Sci 26: 221-232.
19. Casadó V, Cortés A, Mallol J, Pérez-Capote K, Ferré S, et al. (2009) GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers? Pharmacol Ther 124: 248-257.
20. Ciruela F, Casadó V, Mallol J, Canela EI, Lluis C, et al. (1995) Immunological identification of A1 adenosine receptors in brain cortex. J Neurosci Res 42: 818-828.
21. Canals M, Burguen ̃o J, Marcellino D, Cabello N, Canela EI, et al. (2004) Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem 88: 726-734.
22. Guo W, Urizar E, Kralikova M, Mobarec JC, Shi L, et al. (2008) Dopamine D2 receptors form higher order oligomers at physiological expresión levels. EMBO J 27: 2293-2304.
23. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA (2009) Allosteric Communications between protomers of dopamine class A GPCR dimmers modulates activation. Nat Chem Biol 9: 688-695.
24. Casadó V, Cortes A, Ciruela F, Mallol J, et al. (2007) Old and new ways to calculate the affinity of agonists and antagonists interacting with G-proteincoupled monomeric and dimeric receptors: The receptor-dimer cooperativity index. Pharmacol Ther 116: 343-354.
25. Casadó V, Martí T, Franco R, Lluis C, Mallol J, et al. (1990) A method for binding parameters estimation of A1 adenosine receptor subtype: a practical approach. Anal Biochem 184: 117-123.
26. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2007) Targeting adenosine A2A receptors in Parkinson's disease Trends Neurosci 29: 647-654.
27. Jenner P (2003) A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD Neurology 61: S32-S8.
28. Stacy M, Silver D, Mendis T, Sutton J, Mori A, et al. (2008) A 12-week, placebocontrolled study (6002-US-006) of istradefylline in Parkinson disease Neurology 70: 2233-2240.
29. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, et al. (2000) Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone J Nucl Med 41: 65-70.
30. Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, et al. (2002) Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 446: 75-82.
31. Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, et al. (2010) A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease FASEB J 24: 587-598.